OUR PRODUCT PORTFOLIO
Explore Rxilient’s lineup of products, featuring both existing market-ready treatments and upcoming innovations poised for launch or currently in the final stages of regulatory approval. Our carefully curated selection is designed to meet diverse health needs, ensuring high-quality and innovative solutions reach the market swiftly. This section provides insights into our comprehensive healthcare offerings that are transforming patient care across various therapeutic areas.
Category:
EmboLog® S
(Degradable Starch Microspheres) for injection
EyeOP1®
Glaucoma HIFU therapy
BIO Plug™
(Polydioxanone) punctum plugs
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Hecera®
Eczema skin care range
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Ilumetri®
(Tildrakizumab) 100 mg/ml injection
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Lumeblue®
(Methylene blue MMX) tablet
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Lumirix®
(Ruxolitinib) 1.5% cream
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Octarix®
(Omfiloctocog alfa) for injection
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Rxolve®
(High Molecular Weight – Hyaluronic acid) eyedrops
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
Tuoyi™
(toripalimab) for injection
Disclaimer: This product is not yet available for commercial release. Ownership of rights does not imply current market availability. Please consult your local Rxilient representative for more information regarding the status and anticipated availability of this product.
